Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eradicil is a non-biological laundry disinfectant and detergent additive designed to eliminate fungal spores and bacteria from clothing, towels, and bed linen. Developed by V Pharma, it contains broad-spectrum antimicrobial and fungicidal agents, specifically 2-phenylphenol and chlorocresol. The product is intended for use as an adjunct to topical and systemic antimicrobial treatments to prevent cross-infection and self-re-infection in patients suffering from conditions such as athlete's foot (tinea pedis), fungal nail infections (onychomycosis), and jock itch (tinea cruris). It is effective at laundry temperatures as low as 30°C and complies with British and European standards (BS EN 1276 and BS EN 1650) for antibacterial and antifungal activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Eradicil.